Since previous reports demonstrated that aggregated AIMP2 can interact with α-synuclein and facilitate α-synuclein aggregation in Parkinson’s disease (PD) patients [31,32], aggregated AIMP2 might bind to proteins that regulate oligodendrocyte development, myelination, or molecular pathogenesis in patients with HLD17. This evidence concerns the gene AIMP2 and leukodystrophy, hypomyelinating, 17.